Evaluation of responses to vitamin D3 (cholecalciferol) in patients on dialysis: a systematic review and meta-analysis
Xu C, Li YC, Zhao SM, Li ZX
Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 8 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-04-01 · J Investig Med · vol. 64 · número 5 · págs. 1050–1059
- Editorial
- SAGE Publishing
- Citado
- 11 citas · más que el 36% de estudios similares · 0.2× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Pharmacological Effects and Toxicity Studies
- Palabras clave
- Cholecalciferol, Medicine, Vitamin D and neurology, Internal medicine, Placebo, Parathyroid hormone, Calcitriol, Dialysis, vitamin D deficiency, Hemodialysis, Kidney disease, Vitamin, Endocrinology, Gastroenterology, Calcium
- MeSH
- humans, calcium, phosphorus, cholecalciferol, parathyroid hormone, renal dialysis, sensitivity and specificity, publication bias, outcome assessment, health care
4 autores
- Xu Chen🇨🇳Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Yanchun Li🇨🇳Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Sumei Zhao🇨🇳Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Zhongxin Li🇨🇳 · autor de correspondenciaBeijing Luhe Hospital Affiliated to Capital Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Vitamin D plays a key role in mineral metabolism and its deficiency is often noted in patients on dialysis for end-stage renal disease (ESRD). We evaluated the efficacy and responses to vitamin D3 (cholecalciferol) in patients undergoing dialysis for ESRD. Randomized controlled trials or prospective studies comparing vitamin D3 supplementation to placebo in patients with ESRD on dialysis were searched from medical databases using the terms, 'Calcitriol/Cholecalciferol, vitamin D, chronic kidney disease, hemodialysis, serum calcium, parathyroid hormones (PTH), phosphorus, 25(OH)D, and 1,25(OH)2D'. The outcomes analyzed were serum calcium, PTH, phosphorus, 25(OH)D, and 1,25(OH) 2D levels. Of the 259 records identified, 9 studies with a total of 368 patients were chosen for the current meta-analysis. The number of patients, age, and gender distribution among the groups were comparable. Results reveal a greater increase in both 25(OH)D (Pooled difference in means=0.434, 95% CI 0.174 to 0.694, p=0.001) and 1,25(OH) 2D (Pooled difference in means=0.978, 95% CI 0.615 to 1.34, p<0.001) in the treatment arm, as compared to the placebo. There was no difference in the serum calcium or PTH among the two groups. However, patients in the treatment arm had a significant increase in phosphorus levels (Pooled difference in means=0.434, 95% CI 0.174 to 0.694, p=0.001). Vitamin D supplementation facilitated the maintenance of increased levels of 25(OH) D and 1,25(OH) 2D in patients undergoing dialysis for ESRD. This increase in vitamin D was not associated with hypercalcemia or significant changes in PTH levels.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.